AstraZeneca Pharma India Ltd. — Interim / Quarterly Report 2021

Jun 2, 2021

June 2, 2021

The Manger - Listing BSE Limited Corporate Relationship Dept., 1st Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

National Stock Exchange of India Ltd. Exchange plaza, 5th Floor, Plot No.C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Disclosure of Related Party Transactions

Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN

Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended March 31, 2021 for your information and records.

For AstraZeneca Pharma India limited

PRATAP RUDRA BHUVANAG IRI Digitally signed by PRATAP RUDRA BHUVANAGIRI Date: 2021.06.02 16:07:03 +05'30'

Pratap Rudra Company Secretary & Legal Counsel

AstraZeneca Pharma India Limited

Disclosure of related party transactions for the half year ended 31 March, 2021

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018 (All amounts in Rs.million)

(i) Names of related parties and related party relationship

(a) Related parties where control exists and/or where transactions have occurred:

Name of the entity	Name of relationship
Holding Company	AstraZeneca Pharmaceuticals AB, Sweden
Holding Company of AstraZeneca Pharmaceuticals AB, Sweden	AstraZeneca AB, Sweden
Holding Company of AstraZeneca AB, Sweden	AstraZeneca Treasury Limited, United Kingdom
Ultimate Holding Company	AstraZeneca Plc, United Kingdom
Fellow subsidiaries with whom the company had transactions during theyear	AstraZeneca Singapore Pte Ltd, SingaporeAstraZeneca Pharmaceuticals LP, USAAstraZeneca UK Limited, United KingdomP.T. AstraZeneca IndonesiaAstraZeneca Pty Ltd, AustraliaAstraZeneca SDN Bhd, Malaysia
Employees' Benefit Plans	AstraZeneca Pharma India Limited Employees Gratuity Fund TrustAstraZeneca Pharma India Limited Management Staff ProvidentFund TrustAstraZeneca Pharma India Limited Management StaffSuperannuation Fund Trust
b) Key Management Personnel- Managing Director	Mr. Gagandeep Singh Bedi
- Director and Chief Financial Officer	Mr. Rajesh Marwaha
- Non-Executive Directors	Mr. Ian John Parish (upto 18 May, 2020)Mr. Ankush Nandra (w.e.f. 18 May, 2020)Ms. Weiying Sarah Wang
c) Independent Directors	Mr. Narayan K SeshadriMs. Revathy AshokMs. Kimsuka Narasimhan

(ii) Details of the transactions with the related parties during the period 01 October 2020 to 31 March 2021 :

Purchase of raw materials and traded goods
AstraZeneca UK Limited, United Kingdom	876.3
AstraZeneca AB, Sweden	18.3
Payment towards reimbursement of expenses
AstraZeneca Pty Ltd, Australia	6.6

AstraZeneca Pharma India Limited Disclosure of related party transactions for the half year ended 31 March, 2021 In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018 (All amounts in Rs.million)

Sale of services
AstraZeneca AB, Sweden	91.6
Recovery of reimbursable expenses
AstraZeneca UK Limited, United Kingdom	44.6
AstraZeneca AB, Sweden	10.7
AstraZeneca Singapore Pte Ltd, Singapore	13.6
AstraZeneca Pharmaceuticals LP, USA	66.8
AstraZeneca SDN Bhd, Malaysia	4.4
Contribution to Trusts
AstraZeneca Pharma India Limited Employees Gratuity Fund Trust	90.0
AstraZeneca Pharma India Limited Management Staff Provident Fund	68.7
Trust
AstraZeneca Pharma India Limited Management Staff Superannuation	6.5
Fund Trust
(iii) (a) Transactions with Key Management Personnel
Salary and perquisites
Short-term employee benefits	25.6
Long-term employee benefits	8.4
Post employment benefits	19.0
Employee share compensation expenses	2.8
	55.8

Sitting fees paid to independent directors 1.9

AstraZeneca Pharma India Limited Disclosure of related party transactions for the half year ended 31 March, 2021 In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018 (All amounts in Rs.million)

(iv) Details of balances receivable from and payable to related parties as at 31, March 2021 are as follows:

Other current financial assets	42.1
AstraZeneca UK Limited, United Kingdom	27.1
AstraZeneca Pharmaceuticals LP, USA	5.0
AstraZeneca Singapore Pte Ltd, Singapore	7.2
AstraZeneca SDN Bhd, Malaysia	2.8
Trade receivables	85.1
AstraZeneca AB, Sweden	85.1
Trade payables	414.4
AstraZeneca UK Limited, United Kingdom	361.7
AstraZeneca AB, Sweden	49.0
AstraZeneca Pty Ltd, Australia	3.7